Peptide LocalCompare price, evidence & access
Search /Compare vendors
Locations/India/Retatrutide
Purchase and availability checkRetatrutide in India

Can you buy Retatrutide in India?

This page does not establish a legitimate retail purchase from the compound name or an online listing alone. Retatrutide is an investigational clinical program.

Direct answers →Open official records →Open the interactive status check
Evidence lane
Investigational clinical program
Destination
India
Source records
3
Reviewed
24 July 2026
ByPeptide Local Editorial DeskUpdated 24 July 2026How we review
Direct answers

What this exact search can and cannot establish.

Each answer stays attached to the compound identity and destination records. This is a verification guide, not medical or legal advice, a seller recommendation, or proof of availability.

01

Can you buy Retatrutide in India?

This page does not establish a legitimate retail purchase from the compound name or an online listing alone. Retatrutide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below. Before acting on an offer, match the exact product, authorization, seller identity, and supply route in the official records below.

02

Which official records should be checked for Retatrutide in India?

Resolve the exact identity of Retatrutide through TRIUMPH-1 Phase 3 study - NCT05929066 from ClinicalTrials.gov. Then search Approved new drugs from Central Drugs Standard Control Organization for the destination product record and Drug and quality alerts from Central Drugs Standard Control Organization for the seller, establishment, or supply route in India. A match in one record does not replace the other two checks.

03

Does an online listing prove Retatrutide is authorized or available in India?

No. A page using the name Retatrutide, local currency, a domestic delivery claim, or a familiar package image is only a lead. This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status. For India, the exact product, presentation, seller identity, current record status, and claimed supply route must resolve through the official sources on this page.

Live trial footprint

Retatrutide clinical trials in India

5 study records currently list 75 locations in this country, including 10 locations individually marked Recruiting.

Registry update: 24 July 2026
Study records
5
Listed locations
75
Recruiting locations
10
Records with local recruiting sites
1
NCT07165028
Study-wide statusRecruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Listed locations
20
Recruiting locations
10
Registry update
2026-07-17
NCT06383390
Study-wide statusActive, not recruiting

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Listed locations
19
Recruiting locations
0
Registry update
2026-07-20
NCT05929066
Study-wide statusCompleted

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Listed locations
14
Recruiting locations
0
Registry update
2026-06-03
NCT05929079
Study-wide statusActive, not recruiting

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Listed locations
14
Recruiting locations
0
Registry update
2026-04-13
NCT06354660
Study-wide statusCompleted

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Listed locations
8
Recruiting locations
0
Registry update
2026-03-05
Continue the exact comparison

Related country and compound records.

Compare another tracked name in India, or keep Retatrutide fixed and change the destination within Asia-Pacific. The identity, product, and seller checks remain separate.

Continue the exact comparison

Retatrutide in Asia-Pacific

Retatrutide across 42 countries
Identity before availability

A name alone cannot establish a local verdict.

Retatrutide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.

Primary identity source: TRIUMPH-1 Phase 3 study - NCT05929066 / ClinicalTrials.gov ↗
Three-record verification path

Identity. Product. Seller or supply.

A credible result must keep these separate. The official links answer different questions and should be checked in sequence.

TRIUMPH-1 Phase 3 study - NCT05929066

TRIUMPH-1 Phase 3 study - NCT05929066 is maintained by ClinicalTrials.gov. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open TRIUMPH-1 Phase 3 study - NCT05929066 ↗

Approved new drugs

Approved new drugs is maintained by Central Drugs Standard Control Organization. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Approved new drugs ↗

Drug and quality alerts

Drug and quality alerts is maintained by Central Drugs Standard Control Organization. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Drug and quality alerts ↗
India / Country guide

India market context.

India's medicine oversight combines central responsibilities with state licensing and enforcement. CDSCO publishes new-drug approvals and quality or spurious-product alerts, but neither list by itself verifies a clinic, pharmacy, imported research listing, or local seller claim.

  • CDSCO's approved new-drug page publishes dated national approval lists, including a 2026 list, and should be checked for the exact product context.
  • The CDSCO alert index separately publishes quality, spurious-product, recall, and related notices that can change the evidence for a named batch or offer.
  • A peptide seller page, laboratory report, or foreign shipping claim is not a substitute for the relevant central product and state establishment records in India.
Destination checklist

Repeat the country checks before comparing any offer.

The country guide supplies the local verification sequence. It does not convert an online listing into an authorized product or verified seller.

01

Check the central approval list

Search CDSCO's approved new-drug records for the exact name and approval period. Do not treat a foreign authorization, sponsor announcement, or ingredient match as an Indian approval entry.

02

Review current quality alerts

Check CDSCO alerts for not-of-standard-quality and spurious batches. An approval record and a later batch alert answer different questions and both may matter.

03

Identify the state record

Pharmacy and sale permissions may depend on the relevant State Drug Control authority, so match the business and jurisdiction instead of assuming a central product entry verifies the seller.

Primary evidence

Audit every source used by this page.

Open the live record and confirm its current status. A linked source begins the verification process; it does not mean Peptide Local authenticated a product or seller.

01
NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightClinicalTrials.gov
02
Approved new drugsCentral Drugs Standard Control Organization
03
Drug and quality alertsCentral Drugs Standard Control Organization
04
What to know about retatrutideEli Lilly and Company
05
Retatrutide study search in IndiaClinicalTrials.gov
06
NCT07165028: A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)ClinicalTrials.gov
07
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)ClinicalTrials.gov
08
NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightClinicalTrials.gov
09
NCT06354660: Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)ClinicalTrials.gov
Audit and handoff

Keep the exact record attached.